249 related articles for article (PubMed ID: 917456)
41. [Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].
Calbo L; Gorgone S; Palmeri R; Salibra M; Melita P
Chir Ital; 1983 Aug; 35(4):519-25. PubMed ID: 6680859
[TBL] [Abstract][Full Text] [Related]
42. Malignant melanoma.
Spitler LE
J Invest Dermatol; 1976 Sep; 67(3):435-41. PubMed ID: 787436
[TBL] [Abstract][Full Text] [Related]
43. [Immunotherapy of malignant melanomas].
Macher E
Haematol Blood Transfus; 1978; 21():285-91. PubMed ID: 738638
[No Abstract] [Full Text] [Related]
44. BCG stimulation of immune responsiveness in patients with malignant melanoma. Preliminary report.
Gutterman J; Mavligit G; McBride C; Frei E; Hersh EM
Cancer; 1973 Aug; 32(2):321-7. PubMed ID: 4722915
[No Abstract] [Full Text] [Related]
45. Immunotherapy of human malignant melanoma with oil-attached BCG cell-wall skeleton.
Yamamura Y; Yoshizaki K; Azuma I; Yagura T; Watanabe T
Gan; 1975 Aug; 66(4):355-63. PubMed ID: 1102379
[TBL] [Abstract][Full Text] [Related]
46. Critical analysis of treatment of stage II and stage III melanoma patients with immunotherapy.
Jewell WR; Thomas JH; Sterchi JM; Morse PA; Humphrey LJ
Ann Surg; 1976 May; 183(5):543-9. PubMed ID: 776107
[TBL] [Abstract][Full Text] [Related]
47. In vitro assay of cell-mediated immunity in BCG therapy of malignant melanoma: a preliminary report.
Nathanson L; Clark DA
Natl Cancer Inst Monogr; 1973 Dec; 39():221-4. PubMed ID: 4595321
[No Abstract] [Full Text] [Related]
48. Common human melanoma membrane antigens detected by mixed hemadsorption microassay with serum from a patient undergoing immunotherapy with autologous tumor cells.
Liao SK; Leong SP; Sutherland CM; Dent PB; Kwong PC; Krementz ET
Cancer Res; 1978 Dec; 38(12):4395-400. PubMed ID: 82477
[No Abstract] [Full Text] [Related]
49. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
[TBL] [Abstract][Full Text] [Related]
50. Demonstration of lymphocyte blastogenesis--inhibiting factors in sera of melanoma patients.
Rangel DM; Golub SH; Morton DL
Surgery; 1977 Aug; 82(2):224-32. PubMed ID: 877866
[TBL] [Abstract][Full Text] [Related]
51. The use of oral BCG in the treatment or metastatic malignant melanoma.
Pritchard KI; Cowan DH; Baker MA; Osoba D; Phillips RA; Clark DA
Med Pediatr Oncol; 1976; 2(2):173-81. PubMed ID: 785199
[TBL] [Abstract][Full Text] [Related]
52. Results of adjuvant BCG immunotherapy in malignant melanoma.
Wätzig V; Knopf B
Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
[TBL] [Abstract][Full Text] [Related]
53. BCG immunotherapy in previously treated malignant melanoma patients.
Mujagić H; Kolarić K; Malenica B; Nola P
Biomedicine; 1979 Jun; 30(2):95-102. PubMed ID: 476270
[TBL] [Abstract][Full Text] [Related]
54. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.
Berd D; Mastrangelo MJ
Cancer Invest; 1988; 6(3):337-49. PubMed ID: 3167614
[TBL] [Abstract][Full Text] [Related]
55. Effectiveness of systemic BCG therapy in advanced melanoma.
El-Domeiri AA; Nika B; Hsia WC; Crispen R; Sabet TY; Gupta TK
Arch Surg; 1977 Mar; 112(3):257-9. PubMed ID: 843215
[TBL] [Abstract][Full Text] [Related]
56. Adjuvant immunotherapy with BCG in stage II malignant melanoma.
Byrne MJ; Van Hazel G; Reynolds PM; Lemish WM; Holman CD
J Surg Oncol; 1983 Jun; 23(2):114-6. PubMed ID: 6343725
[TBL] [Abstract][Full Text] [Related]
57. Immunopathologic changes in patients with cutaneous malignant melanoma following intratumoral inoculation BCG: correlation with cell-mediated immunity.
Lieberman R; Epstein W; Fudenberg HH
Int J Cancer; 1974 Sep; 14(3):401-16. PubMed ID: 4617711
[No Abstract] [Full Text] [Related]
58. [Intranodular treatment with BCG of cutaneous and subcutaneous metastases of malignant melanoma (author's transl)].
Balzarini GP; Cascinelli N; Fontana V; Veronesi U
Tumori; 1974; 60(4):345-52. PubMed ID: 4439501
[No Abstract] [Full Text] [Related]
59. [Activity of 2,4 dinitrochlorbenzene skin tests during the course of immunotherapy of malignant melanomas].
Richter J; Duchková H; Kubíková M
Cas Lek Cesk; 1975 Sep; 114(39):1201-3. PubMed ID: 1182748
[No Abstract] [Full Text] [Related]
60. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]